Article
Oncology
Paul Koller, Natalia Baran, Karine Harutyunyan, Antonio Cavazos, Saradhi Mallampati, Renee L. Chin, Zhou Jiang, Xian Sun, Heng-Huan Lee, Jennifer L. Hsu, Patrick Williams, Xuelin Huang, Michael A. Curran, Mien-Chie Hung, Marina Konopleva
Summary: This study found that the combination treatment with the tyrosine kinase inhibitor dasatinib and an anti-PD-1 antibody is highly effective in a preclinical model of Philadelphia chromosome positive B-cell acute lymphoblastic leukemia. The treatment decreases tumor burden, improves efficacy, and prolongs survival. Mechanistically, it increases MHC II expression on antigen-presenting cells and promotes influx of these cells into the leukemic bone marrow. The induction of MHC II may also enhance immune memory and impair leukemic engraftment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Yutao Li, Amit Sharma, Maurits Bloemendal, Roland Schmidt-Wolf, Miroslaw Kornek, Ingo Schmidt-Wolf
Summary: CIK cells have cytotoxic effects on B-NHL cells, and a combination therapy of PD-1 inhibitors with CIK cells may offer a potential treatment option for this type of lymphoma. Further in vivo experiments are needed to determine the extent of enhancement of antitumor activity in B-NHL by PD-1 inhibitors.
Article
Oncology
Yi Que, Xiao-Long Zhang, Ze-Xian Liu, Jing-Jing Zhao, Qiu-Zhong Pan, Xi-Zhi Wen, Wei Xiao, Bu-Shu Xu, Dong-Chun Hong, Tian-Hui Guo, Lu-Jun Shen, Wei-Jun Fan, Huo-Ying Chen, De-Sheng Weng, Hai-Rong Xu, Peng-Hui Zhou, Yi-Zhuo Zhang, Xiao-Hui Niu, Xing Zhang
Summary: Combining HDAC class I inhibitor chidamide with anti-PD-1 therapy shows potential clinical benefits in patients with soft tissue sarcoma. The study found frequent amplification of the HDAC gene family in STS, with inhibition of HDAC class I promoting apoptosis, increasing PD-L1 expression, and enhancing the efficacy of immune therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Julia Moreno-Vicente, Jane E. Willoughby, Martin C. Taylor, Steven G. Booth, Vikki L. English, Emily L. Williams, Christine A. Penfold, C. Ian Mockridge, Tatyana Inzhelevskaya, Jinny Kim, H. T. Claude Chan, Mark S. Cragg, Juliet C. Gray, Stephen A. Beers
Summary: This study reveals that the interaction between the Fc region of anti-PD-1 monoclonal antibodies and Fc gamma receptors plays a critical role in therapeutic resistance. The extent of this interaction is determined by the immune environment. Low Fc binding of the antibodies reduces T-cell responses, but can still induce long-term antitumor immunity in immunologically "hot" tumors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Editorial Material
Hematology
Alison J. Moskowitz
Summary: The study by Allen and colleagues demonstrates promising initial results of PD-1 blockade in cHL treatment, showing effective tumor growth inhibition and reduced treatment side effects, potentially becoming a new treatment modality for cHL.
Article
Oncology
Adriana Hepner, Victoria G. Atkinson, James Larkin, Rebecca A. Burrell, Matteo S. Carlino, Douglas B. Johnson, Lisa Zimmer, Katy K. Tsai, Oliver Klein, Serigne N. Lo, Andrew Haydon, Prachi Bhave, Megan Lyle, Lalit Pallan, Ines Pires da Silva, Camille Gerard, Olivier Michielin, Georgina V. Long, Alexander M. Menzies
Summary: This study retrospectively analyzed the efficacy and safety of ipilimumab re-induction in patients with advanced melanoma who developed acquired resistance after combination immunotherapy. The response rate to reinduction therapy was 26%, with a disease control rate of 45%. Clinicians should be cautious of immune-related adverse events, including the recurrence of events observed during induction therapy.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Medicine, Research & Experimental
Angelica Maria Gamboa-Cedeno, Mariangeles Diaz, Nancy Cristaldo, Victoria Otero, Natalia Schutz, Dorotea Fantl, Silvana Cugliari, Marta Zerga, Erica Rojas-Bilbao, Federico Jauk, Hernan Garcia Rivello, Myriam Nunez, Stella Maris Ranuncolo
Summary: The study highlights the potential of BCL-2 as a prognostic biomarker and a new therapeutic target in classical Hodgkin Lymphoma (cHL). Additionally, it reveals the cytotoxic effect of venetoclax in human cHL cell lines for the first time.
Article
Oncology
Meijing Liu, Haobin Deng, Juan Mu, Qing Li, Yedi Pu, Yili Jiang, Qi Deng, Zhengzi Qian
Summary: For patients with refractory B-cell lymphoma, the second-time humanized CD19 chimeric antigen receptor (CD19-CAR) T-cell therapy combined with ibrutinib salvage treatment showed promising therapeutic effects in some patients, leading to complete response or partial remission. However, this treatment approach also resulted in higher levels of cytokine release syndrome and more severe hematological toxicity compared to the first-time therapy.
Article
Oncology
April A. N. Rose, Susan M. Armstrong, David Hogg, Marcus O. Butler, Samuel D. Saibil, Diana P. Arteaga, Thiago Pimentel Muniz, Deirdre Kelly, Danny Ghazarian, Ian King, Zaid Saeed Kamil, Kendra Ross, Anna Spreafico
Summary: The study found that primary melanoma tumor type and genomic subtype serve as independent predictive markers of clinical progression-free survival and overall survival in patients with metastatic melanoma receiving anti-PD1 ICI. Further evaluation in prospective clinical trials is needed to determine the value of primary tumor type and genomic subtype, including NRAS, as predictive markers. Biologic subtypes may aid in clinical decision-making when deciding between combination ICI treatment (anti-PD1 +/- anti-CTLA4) versus anti-PD1 alone for patients with metastatic melanoma.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Oncology
Mohammadsaleh Jahangir, Omid Yazdani, Mohammad Saeed Kahrizi, Sara Soltanzadeh, Hamidreza Javididashtbayaz, Azam Mivefroshan, Saba Ilkhani, Romina Esbati
Summary: PD-1/PD-L1 blockade therapy has significant clinical activity in the treatment of renal cell carcinoma, but only a small portion of patients show positive response. Recent studies have shown that combining other treatment modalities with PD-1/PD-L1 blockade therapy may improve clinical responses in renal cell carcinoma patients.
CANCER CELL INTERNATIONAL
(2022)
Article
Oncology
Prachi Bhave, Tasnia Ahmed, Serigne N. Lo, Alexander Shoushtari, Anne Zaremba, Judith M. Versluis, Joanna Mangana, Michael Weichenthal, Lu Si, Thierry Lesimple, Caroline Robert, Claudia Trojanello, Alexandre Wicky, Richard Heywood, Lena Tran, Kathleen Batty, Florentia Dimitriou, Anna Stansfeld, Clara Allayous, Julia K. Schwarze, Meghan J. Mooradian, Oliver Klein, Inderjit Mehmi, Rachel Roberts-Thomson, Andrea Maurichi, Hui-Ling Yeoh, Adnan Khattak, Lisa Zimmer, Christian U. Blank, Egle Ramelyte, Katharina C. Kaehler, Severine Roy, Paolo A. Ascierto, Olivier Michielin, Paul C. Lorigan, Douglas B. Johnson, Ruth Plummer, Celeste Lebbe, Bart Neyns, Ryan Sullivan, Omid Hamid, Mario Santinami, Grant A. McArthur, Andrew M. Haydon, Georgina Long, Alexander M. Menzies, Matteo S. Carlino
Summary: Acral melanoma is a rare subtype with poor prognosis, and there is a lack of prospective clinical trial evidence on the efficacy of checkpoint inhibitors in this population. The study found that initial anti-PD-1/ipilimumab combination had a significantly higher ORR compared to anti-PD-1 alone, but this benefit did not translate to improved OS in this retrospective cohort. Primary site did not impact treatment outcomes.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Medicine, Research & Experimental
Yumei Gao, Simeng Hu, Ruoyan Li, Shanzhao Jin, Fengjie Liu, Xiangjun Liu, Yingyi Li, Yicen Yan, Weiping Liu, Jifang Gong, Shuxia Yang, Ping Tu, Lin Shen, Fan Bai, Yang Wang
Summary: This study demonstrated that PD-1 acts as a tumor suppressor for malignant T cells with oncogenic TCR activation, based on the analysis of a patient with advanced cutaneous T cell lymphoma who experienced hyperprogression upon anti-PD-1 treatment. PD-1 blockade led to the activation and proliferation of CD4+ malignant T cells, which exhibited functional PD-1 expression and an exhausted status. Somatic amplification of PRKCQ in the malignant T cells resulted in an oncogenic activation of the TCR signaling pathway.
Article
Engineering, Biomedical
Juyoung Hwang, Eun-Koung An, Wei Zhang, Hae-Bin Park, So -Jung Kim, Dhananjay Yadav, Jihoe Kim, Inho Choi, Minseok Kwak, Peter CW. Lee, Xiaoyan Zhang, Jianqing Xu, Jun-O Jin
Summary: This study found that recombinant murine programmed death-1 (rmPD-1) protein can function as an immune checkpoint blockade for cancer treatment. Additionally, thermal responsive hybrid nanoparticles (piHNPs) decorated with rmPD-1 have a promoting effect on anti-cancer immunity and can prevent cancer metastasis and recurrence.
Review
Oncology
Chia-Jung Li, Li-Te Lin, Ming-Feng Hou, Pei-Yi Chu
Summary: Significant progress has been made in understanding the role of PD-L1 in breast cancer, especially in TNBC. Early clinical trials of PD-L1/PD-1 inhibitors have shown efficacy in refractory metastatic breast cancer patients, particularly in TNBC. Mechanisms and factors influencing the immunoediting process have been summarized and analyzed in detail.
Review
Immunology
Bahman Abedi Kiasari, Arash Abbasi, Nadia Ghasemi Darestani, Nasim Adabi, Arsalan Moradian, Yalda Yazdani, Golsa Sadat Hosseini, Nasrin Gholami, Sheida Janati
Summary: Immune checkpoint inhibitor nivolumab has greatly improved the treatment outcomes for advanced cancer patients. However, monotherapy with nivolumab is not effective in a large proportion of patients. The rational combination of nivolumab with conventional and targeted therapies has been shown to enhance its efficacy.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)